Drug Information

Drug General Information
Drug ID
D08JSQ
Former ID
DIB003179
Drug Name
DS-3032
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [524327]
Company
Daiichi sankyo
Target and Pathway
Target(s) Ubiquitin-protein ligase E3 Mdm2 Target Info Inhibitor [525403]
KEGG Pathway FoxO signaling pathway
Cell cycle
p53 signaling pathway
Ubiquitin mediated proteolysis
Endocytosis
PI3K-Akt signaling pathway
Thyroid hormone signaling pathway
Epstein-Barr virus infection
Pathways in cancer
Transcriptional misregulation in cancer
Viral carcinogenesis
Proteoglycans in cancer
MicroRNAs in cancer
Glioma
Prostate cancer
Melanoma
Bladder cancer
Chronic myeloid leukemia
PANTHER Pathway Insulin/IGF pathway-protein kinase B signaling cascade
p53 pathway
Ubiquitin proteasome pathway
P53 pathway feedback loops 1
p53 pathway feedback loops 2
Pathway Interaction Database ErbB4 signaling events
p73 transcription factor network
ATR signaling pathway
ATM pathway
Glucocorticoid receptor regulatory network
Sumoylation by RanBP2 regulates transcriptional repression
Direct p53 effectors
Regulation of Androgen receptor activity
Validated transcriptional targets of deltaNp63 isoforms
Aurora A signaling
Validated transcriptional targets of TAp63 isoforms
p53 pathway
Regulation of retinoblastoma protein
Reactome AKT phosphorylates targets in the cytosol
Oxidative Stress Induced Senescence
Oncogene Induced Senescence
Trafficking of AMPA receptors
Constitutive Signaling by AKT1 E17K in Cancer
Stabilization of p53
WikiPathways DNA Damage Response (only ATM dependent)
DNA Damage Response
ErbB Signaling Pathway
Senescence and Autophagy in Cancer
Tryptophan metabolism
G1 to S cell cycle control
Copper homeostasis
Bladder Cancer
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
PIP3 activates AKT signaling
Apoptosis
ATM Signaling Pathway
Retinoblastoma (RB) in Cancer
Integrated Pancreatic Cancer Pathway
Prostate Cancer
Signaling Pathways in Glioblastoma
Integrated Breast Cancer Pathway
Integrated Cancer pathway
Cell Cycle
Cell Cycle Checkpoints
TP53 Network
miRNA Regulation of DNA Damage Response
Androgen receptor signaling pathway
References
Ref 524327ClinicalTrials.gov (NCT01877382) A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health.
Ref 525403Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014 Mar;13(3):217-36. doi: 10.1038/nrd4236.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.